Voluloride(Voluloride) - 药物靶点：ENaC_在研适应症：干眼症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

+ [1]

靶点

ENaC

作用机制

ENaC阻滞剂(上皮细胞钠离子通道阻滞剂)

治疗领域

眼部疾病

在研适应症

干眼症

非在研适应症-

原研机构

Parion Sciences, Inc.

在研机构

Parion Sciences, Inc.Shire Pharmaceuticals Services Ltd.

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C38H67ClN18O4

InChIKeyOKBDJMKISGUWNG-VSGBNLITSA-N

CAS号1498299-91-4

关联

3

项与 Voluloride 相关的临床试验

NCT02824913

/ Terminated临床2期

Randomized, Crossover Study of the Pharmacodynamic Activity of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Characterized by Low Tear Volume

The purpose of this Phase 2a study is to assess changes in tear volume by the non-invasive techniques Ultra High Resolution Optical Coherence Tomography (UHR-OCT) following the administration of P-321 Ophthalmic Solution or Placebo in subjects with tear deficient dry eye disease.

开始日期2016-07-01

申办/合作机构

Parion Sciences, Inc.

NCT02831387

/ Terminated临床2期

Randomized, Double-Masked, Parallel Group Study of P-321 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Disease Assessing Safety and Efficacy Over 28 Days

The purpose of this study is to evaluate the effect of treatment with 0.017% P-321 on Dry Eye Symptoms.

开始日期2016-07-01

申办/合作机构

Parion Sciences, Inc.

NCT02242032

/ Completed临床1期

A Double-Masked, Randomized, Placebo-Controlled Dose Escalation Study of the Safety and Tolerability of P 321 Ophthalmic Solution in Subjects With Dry Eye Disease

The purpose of this study is to assess the safety and tolerability of P-321 Ophthalmic Solution in subjects with mild to moderate dry eye disease.

开始日期2014-07-01

申办/合作机构

Parion Sciences, Inc.

100 项与 Voluloride 相关的临床结果

登录后查看更多信息

100 项与 Voluloride 相关的转化医学

登录后查看更多信息

100 项与 Voluloride 相关的专利（医药）

登录后查看更多信息

1

项与 Voluloride 相关的文献（医药）

2012-09-01·Scandinavian Journal of Immunology4区 · 医学

A Novel Cytotoxic T lymphocyte Epitope Analogue with Enhanced Activity Derived From Cyclooxygenase‐2

4区 · 医学

Article

作者: Y. M. Qi ; M. X. Zhai ; Y. J. He ; M. Sun ; R. R. Shi ; X. Chen ; Y. H. Wu ; W. J. Zhai ; Y. F. Gao ; Z. Y. Wu

AbstractCyclooxygenase‐2 is a promising target for cancer immunotherapy. Here, we designed the analogues p321‐9L and p321‐1Y9L (YLIGETIKL) from cyclooxygenase‐2‐derived native peptide p321. Then, we tested the binding affinity and stability of the analogues and their ability to elicit specific immune response both in vitro (from PBMCs of HLA‐A*02+ healthy donors) and in vivo (from HLA‐A2.1/Kb transgenic mice). Our results indicated that the activity of cytotoxic T lymphocytes induced by p321‐9L and p321‐1Y9L was more potent than that of p321. In conclusion, the epitope analogue, especially p321‐1Y9L, may be a good candidate which could be used to the immunotherapy of patients with tumours expressing cyclooxygenase‐2.

100 项与 Voluloride 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
干眼症	临床2期	-	Parion Sciences, Inc.	-
干眼症	临床2期	-	Shire Pharmaceuticals Services Ltd.	-
干眼综合征	药物发现	美国	Parion Sciences, Inc.	2016-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02831387 (CTgov)	临床2期	干眼综合征	47	P-321 Ophthalmic Solution	糧鏇憲繭網顧製願獵製(襯壓糧膚鬱鏇鬱膚簾積) = 選構積網遞襯構鹽壓築鬱蓋願齋鏇衊鬱鬱壓淵 (壓膚觸窪築鏇簾窪鑰醖, 夢簾鹹糧憲願蓋選廠鏇 ~ 襯憲憲夢廠齋糧選繭鏇) 更多	-	2018-10-11
NCT02824913 (CTgov)	临床2期	干眼综合征	1	P-321 Ophthalmic Solution (P-321 Ophthalmic Solution)	繭淵鹹淵製構齋範顧觸(艱簾觸觸醖蓋餘觸顧網) = 襯膚糧醖蓋艱廠鏇遞構鏇觸衊築齋範鏇構膚構 (構憲壓鑰餘範餘顧鑰範, 觸範廠糧廠齋糧蓋鬱築 ~ 製夢鹹鹹選廠範淵鹽鏇) 更多	-	2018-01-19
NCT02824913 (CTgov)	临床2期	干眼综合征	1	P-321 Ophthalmic Solution placebo (Drug: P-321 Ophthalmic Solution Placebo)	繭淵鹹淵製構齋範顧觸(艱簾觸觸醖蓋餘觸顧網) = 範選齋顧餘鏇範齋構鏇鏇觸衊築齋範鏇構膚構 (構憲壓鑰餘範餘顧鑰範, 積簾窪範鑰繭窪製壓壓 ~ 鏇繭鏇艱壓構淵願齋醖) 更多	-	2018-01-19
ARVO2014	N/A	-	-	P-321 0.1%	(襯蓋製鏇襯醖壓鏇廠觸) = increased slightly during multiple dose administration reaching steady state levels by Day 4 鏇獵鑰膚製窪糧願餘觸 (獵範艱糧繭齋製廠襯構 ) 更多	-	2014-04-01